Physician

Adewale A. Fawole, M.D.

According to 2025 Medicare claims, Adewale Fawole, M.D. (NPI: 1073742359) practices hematology/oncology in the Orlando-Kissimmee-Sanford, FL market, with the plurality of this provider's patient population coming from Lake, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 32163-2040. Fawole is affiliated with the CVS ACO (ACO ID: A5407), participating under the MSSP model.

Fawole's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,470 traditional Medicare patients, billed 349,517 HCPCS/CPT codes, and received $4,441,335 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,881 prescription claims across 423 beneficiaries totaling $7,384,830 in drug costs, led by Revlimid (Lenalidomide). DME data shows 30 claims. Open Payments data shows 162 records totaling $250,848. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $7,595 to $4,441,335. Similarly, Part D prescription costs have risen steadily, from $231,209 to $7,384,830. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	68	93	$7,595
2017	204	475	$36,751
2018	788	1,818	$187,461
2019	940	5,912	$236,125
2020	941	39,500	$669,028
2021	1,211	248,817	$2,945,625
2022	1,160	361,074	$4,413,872
2023	1,368	339,329	$5,370,732
2024	1,470	349,517	$4,441,335

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	11	113	$231,209
2016	36	132	$216,941
2017	80	420	$633,499
2018	33	83	$101,792
2019	13	24	$13,944
2020	94	374	$151,141
2021	271	1,383	$1,572,182
2022	306	1,394	$3,160,110
2023	351	1,380	$3,792,927
2024	423	1,881	$7,384,830

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	39	$16,792
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	31	$672
2023	N/R	42	$3,585
2024	N/R	30	$488

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	470	1,128	$95
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	314	677	$13
96372	Injection of drug or substance under skin or into muscle	315	889	$10
36415	Insertion of needle into vein for collection of blood sample	1,036	2,463	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	1,005	2,616	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	145	3,745	$2,201,967
Scemblix	Asciminib Hydrochloride	11	330	$1,193,711
Venclexta	Venetoclax	67	1,919	$606,822
Jakafi	Ruxolitinib Phosphate	32	960	$543,385
Brukinsa	Zanubrutinib	47	1,410	$498,469

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	17	$337
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	13	$150

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	145	$3,182	Celgene Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	17	$247,666	Novartis Pharmaceuticals Corporation
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Adewale A. Fawole, M.D.?

Tedicare shows public-source Medicare data for Adewale A. Fawole, M.D. (NPI 1073742359), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Adewale A. Fawole, M.D. have ACO affiliation data?

Adewale A. Fawole, M.D. is shown with ACO affiliation data for CVS ACO (MSSP, ACO ID A5407).

What billing organization is linked to Adewale A. Fawole, M.D.?

Adewale A. Fawole, M.D. is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Adewale A. Fawole, M.D. have Open Payments data?

Adewale A. Fawole, M.D. has 162 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.